Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5KYPJ)

• Drug Name: Butorphanol Drug Info
• Synonyms: Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1]

• Therapeutic Class: Analgesics
• Cross-matching ID:
  PubChem CID: 5361092
  ChEBI ID: CHEBI:3242
  CAS Number: CAS 42408-82-2
  TTD Drug ID: DM5KYPJ

Molecule-Related Drug Atlas

Drug(s) Targeting Opioid receptor delta (OPRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Codeine	DMJX6ZG	Allergic rhinitis	CA08.0	Approved	[2]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[5]
Loperamide	DMOJZQ9	Diarrhea	ME05.1	Approved	[6]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[7]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[8]
Carfentanil	DM7ADGX	N. A.	N. A.	Phase 2	[9]
Met-enkephalin	DMSZFTP	Pain	MG30-MG3Z	Phase 2	[10]
AZD-2327	DM8FZOG	Anxiety disorder	6B00-6B0Z	Phase 2	[11]
ADL-5747	DMMUPTN	Pain	MG30-MG3Z	Phase 2	[12]
ADL-5859	DMDQH9A	Rheumatoid arthritis	FA20	Phase 2	[12]

Drug(s) Affected By Mu-type opioid receptor (OPRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alvimopan	DMHR8KW	Gastrointestinal disease	DE2Z	Approved	[13]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[14]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[15]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Oliceridine	DM6MDCF	Acute pain	MG31	Approved	[14]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[20]
Tianeptine	DMYN8MA	Major depressive disorder	6A70.3	Approved	[3]

Drug(s) Affected By Protein kinase C delta type (PRKCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[22]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[23]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[24]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[25]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[26]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[27]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[29]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Agonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Mu-type opioid receptor (OPRM1)	OT16AAT8	OPRM_HUMAN	Gene/Protein Processing	[3]
Protein kinase C delta type (PRKCD)	OTSEH90E	KPCD_HUMAN	Protein Interaction/Cellular Processes	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7591).
• [2] Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
• [3] In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Arch Toxicol. 2020 Nov;94(11):3819-3830. doi: 10.1007/s00204-020-02855-7. Epub 2020 Jul 31.
• [4] Non-canonical Opioid Signaling Inhibits Itch Transmission in the Spinal Cord of Mice. Cell Rep. 2018 Apr 17;23(3):866-877. doi: 10.1016/j.celrep.2018.03.087.
• [5] Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
• [6] Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
• [7] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [8] Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
• [9] Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
• [10] Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
• [11] Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
• [13] The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. doi: 10.1007/s00210-007-0146-x. Epub 2007 Mar 6.
• [14] A G protein-biased ligand at the ?-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.
• [15] Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008 Apr;83(4):559-66.
• [16] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [17] The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. J Ethnopharmacol. 2013 Jun 21;148(1):135-43. doi: 10.1016/j.jep.2013.03.078. Epub 2013 Apr 19.
• [18] Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Pharmacol. 2006 Apr;69(4):1486-91. doi: 10.1124/mol.105.018325. Epub 2006 Jan 24.
• [19] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [20] Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. Neuroimmunomodulation. 2012;19(3):180-6. doi: 10.1159/000331474. Epub 2012 Jan 18.
• [21] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [22] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [23] Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
• [24] Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia. 2000 Nov-Dec;2(6):505-13. doi: 10.1038/sj.neo.7900120.
• [25] Early Transcriptomic Changes upon Thalidomide Exposure Influence the Later Neuronal Development in Human Embryonic Stem Cell-Derived Spheres. Int J Mol Sci. 2020 Aug 3;21(15):5564. doi: 10.3390/ijms21155564.
• [26] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [27] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [28] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [29] Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis. 2011 May;32(5):723-31. doi: 10.1093/carcin/bgr038. Epub 2011 Feb 28.
• [30] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.